Jim Momtazee

We are creative and agile innovators, relentlessly curious about finding new ways to target the biology behind diseases with the greatest unmet need, and determined to do something about it. At Osanni, a development-stage therapeutics company, we are reinventing the process of discovery by approaching the science of disease with modern technology and a beginner’s mindset. Inspired by the principles of Biodesign, we drive capital-efficient development of life-changing medicines for patients and the physicians who care for them. Central to Osanni is our innovation hub, which is optimized for what our team does best: discovering new scientific insights, designing novel drug concepts and efficiently advancing programs to a meaningful proof-of-concept. Once a program is sufficiently de-risked, it graduates into our ecosystem of affiliate companies, which we affectionately call “Avians.” Each Avian takes flight equipped with the dedicated focus, specialized talent, capital and strategic support necessary to scale. Our architecture marries the scientific depth and operational power of a centralized platform with the speed, agility and accountability of independent companies. The result: an opportunity to create and deliver transformative medicines, again and again. We hold patients and the physicians who care for them as our North Star. It guides our purpose, sharpens our decision-making, and defines our impact. Osanni is currently advancing programs in ophthalmology, cardiology and beyond. We are building a highly skilled team, passionate about having an impact on human health. Be part of creating an organization where people enjoy their work and their colleagues are valued for their individuality and cant imagine working anywhere else. Join us.

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

A biopharmaceutical company developing prescription therapies for unmet needs in the field of Food Allergy

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Apollo Therapeutics is a biopharmaceutical company rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Through deep relationships with world-leading universities and scientists, the company identifies programs with strong biological hypotheses and potential to become meaningful new treatment options. Apollo’s portfolio-based model combines a centralized team of drug development ‘architects’ and subject matter experts who are able to rigorously evaluate therapeutic programs in an objective, data-driven manner – prioritizing critical experiments to de-risk programs early. This capital efficiency allows Apollo to focus on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders and rare disease. Apollo’s innovative model was created in late 2015 by three world-leading universities Cambridge, Imperial College London and University College London in partnership with AstraZeneca, GlaxoSmithKline and Johnson & Johnson Innovation. There is significant opportunity ahead of us to bring new treatments to market as our lead programs move into clinical development. We will look to build on our existing collaborations, foster new relationships with additional top academics around the world and in-license drug candidates from new partners. Apollo is funded by Patient Square Capital, Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. We are expanding our operations in Cambridge, UK and Boston, USA. For more information, please visit our website at www.apollotherapeutics.com

Kriya Therapeutics, Inc. is a biopharmaceutical company developing gene therapies for diseases affecting millions of people around the world. With operations in Palo Alto, California and Research Triangle Park, North Carolina, Kriya has raised over $450 million to advance a broad pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases.

Headquartered in Louisville, Kentucky, PharMerica is one of the largest and fastest-growing institutional pharmacy companies in the U.S. With more than 180 long-term care pharmacies in almost every state, we offer a national scope with a local approach, as well as unmatched clinical quality and customer care. With approximately 6,000 dedicated employees, PharMerica employs some of the industry’s best and brightest clinicians and innovators. At PharMerica, you can choose your career path, from hospital or long-term care pharmacy to corporate and non-clinical opportunities. To support your quality of life, we offer educational opportunities, remote work, and a comprehensive benefits package.

Covenant Physician Partners is a physician services company that partners with leading healthcare providers across the country to grow thriving practices and centers while advancing clinical excellence. Covenant’s national network of leading practices across the outpatient care continuum brings operational expertise, financial backing and clinical best practices to fuel growth. With a 10+ year track record as a valued partner to ambulatory surgery centers, Covenant addresses the evolving needs of today’s physicians and for the future of healthcare. We work hand-in-hand with our partners to Improve Health Together. Our physician partners span across the country and are supported through business, clinical and operational expertise. At our Nashville Service Center, we provide physician partners with a full suite of business support services such as human resources, billing, compliance, regulatory, payor relations, contract negotiations, information technology, clinical services, accounting, and payroll, allowing our partners to focus on providing quality, personalized care for their patients.

Ajax Health deploys capital and leverages operational experience to accelerate healthcare innovation across medical devices, digital health, healthcare services and biotechnology. We partner with entrepreneurs across all stages of a company's lifecycle and leverage deep domain expertise to support business strategy, clinical & regulatory, R&D and M&A.

BridgeBio finds, develops, and delivers breakthrough medicines for genetic diseases. Millions worldwide are afflicted with genetic diseases, but small patient populations and industry reluctance to conduct early-stage development means that for many, treatments have not been forthcoming. We are committed to bridging this gap: between business case and scientific possibility, between patient and hope. BridgeBio creates a bridge from remarkable advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio is committed to developing leaders as well as drugs. We are looking for individuals whose passion for creating life-changing medicines will inspire hands-on engagement and the dogged pursuit of novel solutions in the face of adversity.

Spirox is committed to improving the quality of life for patients suffering from nasal obstruction, a condition that affects more than 20 million individuals in the United States. The Menlo Park-based company’s first product—the LATERA absorbable nasal implant—is designed to address one of the most common, yet undertreated, causes of nasal obstruction today, nasal valve collapse (NVC). For more information, please visit www.spiroxmed.com. LATERA is available in the U.S. only. Spirox and LATERA and its logos are trademarks of Spirox, Inc.

We create transformative POCUS solutions by infusing premium ultrasound performance with industry-leading AI to give more clinicians more patient information more quickly. https://linktr.ee/echonous.kosmos

EchoNous creates transformative point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools, providing more clinicians with increased information faster. Visit our website at https://www.echonous.com/

With nearly 37,000 team members, Global Medical Response teams deliver compassionate, quality medical care, primarily in the areas of emergency and patient relocation services in the United States, the District of Columbia and around the world. GMR was formed by combining the industry leaders in air, ground, managed medical transportation, and community, industrial/specialty and wildland fire services. Each of our companies have long histories of proudly serving the communities where we live: American Medical Response (AMR), Rural Metro Fire, Air Evac Lifeteam, REACH Air Medical Services, Med-Trans Corporation, AirMed International and Guardian Flight.

We are creative and agile innovators, relentlessly curious about finding new ways to target the biology behind diseases with the greatest unmet need, and determined to do something about it. At Osanni, a development-stage therapeutics company, we are reinventing the process of discovery by approaching the science of disease with modern technology and a beginner’s mindset. Inspired by the principles of Biodesign, we drive capital-efficient development of life-changing medicines for patients and the physicians who care for them. Central to Osanni is our innovation hub, which is optimized for what our team does best: discovering new scientific insights, designing novel drug concepts and efficiently advancing programs to a meaningful proof-of-concept. Once a program is sufficiently de-risked, it graduates into our ecosystem of affiliate companies, which we affectionately call “Avians.” Each Avian takes flight equipped with the dedicated focus, specialized talent, capital and strategic support necessary to scale. Our architecture marries the scientific depth and operational power of a centralized platform with the speed, agility and accountability of independent companies. The result: an opportunity to create and deliver transformative medicines, again and again. We hold patients and the physicians who care for them as our North Star. It guides our purpose, sharpens our decision-making, and defines our impact. Osanni is currently advancing programs in ophthalmology, cardiology and beyond. We are building a highly skilled team, passionate about having an impact on human health. Be part of creating an organization where people enjoy their work and their colleagues are valued for their individuality and cant imagine working anywhere else. Join us.

Headquartered in Austin, Texas, Hanger, Inc. is a leading provider of orthotic and prosthetic (O&P) patient care services and products. The company operates as an ecosystem of diversified companies delivering complementary solutions to individuals and providers with O&P needs, and is organized in two business segments – Patient Care and Products & Services. Through its Patient Care segment, Hanger provides comprehensive, outcomes-based O&P services to individuals of all ages at more than 925 Hanger Clinic locations nationwide. Through its Products & Services segment, Hanger serves the broader O&P community and skilled nursing facilities through designing and distributing branded and private label O&P devices, products and components, providing consulting services, and offering post-acute rehabilitative solutions. Rooted in clinical research, excellence, and innovation, Hanger is a purpose-driven company focused on empowering human potential. For more information, visit corporate.hanger.com.

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

A biopharmaceutical company developing prescription therapies for unmet needs in the field of Food Allergy

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.